Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost in Patients With Spinal Metastases

Antonio Pontoriero, MD¹, Giuseppe Iati, MD¹, Alberto Cacciola, MD², Alfredo Conti, MD, PhD³, Anna Brogna, PhD⁴, Carmelo Siragusa, PhD⁴, Gianluca Ferini, MD², Valerio Davi, MD², Consuelo Tamburella, MD², Laura Molino, MD², Domenico Cambareri, MD², Cesare Severo, MD², Silvana Parisi, MD², Nicola Settineri, PhD⁵, Isidora Ielo, PhD⁴, and Stefano Pergolizzi, MD²

Abstract
Stereotactic body radiation therapy in patients with spine metastases maximizes local tumor control and preserves neurologic function. A novel approach could be the use of stereotactic body radiation therapy with simultaneous integrated boost delivery modality. The aim of the present study is to report our experience in the treatment of spine metastases using a frameless radiosurgery system delivering stereotactic body radiation therapy–simultaneous integrated boost technique. The primary endpoints were the pain control and the time to local progression; the secondary ones were the overall survival and toxicity. A total of 20 patients with spine metastases and 22 metastatic sites were treated in our center with stereotactic body radiation therapy–simultaneous integrated boost treatments between December 2007 and July 2018. Stereotactic body radiation therapy–simultaneous integrated boost treatments were delivered doses of 8 to 10 Gy in 1 fraction to isodose line of 50%. The median follow-up was 35 months (range: 12-110). The median time to local progression for all patients was not reached and the actuarial 1-, 2-, and 3-years local free progression rate was 86.36%. In 17 of 20 patients, a complete pain remission was observed and 3 of 20 patients had a partial pain remission (complete pain remission + partial pain remission: 100%). The median overall survival was 38 months (range 12-83). None of the patients experienced neither radiation adverse events (grade 1-4) nor reported pain flair reaction. None of the patients included in our series experienced vertebral compression fracture. Spine radiosurgery with stereotactic body radiation therapy–simultaneous integrated boost is safe. The use of this modality in spine metastases patients provides an excellent local control.

Keywords
SBRT, simultaneous integrated boost, CyberKnife, oligometastatic, robotic, radiosurgery

¹ Radiation Oncology Unit, A.O.U. “G. Martino”, Messina, Italy
² Radiation Oncology Unit, Department of Biomedical, Dental Sciences and of Morphological and Functional Images, University of Messina, Italy
³ Neurosurgery Unit, Department of Biomedical, Dental Sciences and of Morphological and Functional Images, University of Messina, Italy
⁴ Medical Physics Unit, A.O.U. “G. Martino”, Messina, Italy
⁵ Medical Physics of Radiation Oncology Unit, A.O. “Papardo”, Messina, Italy

Corresponding Author:
Alberto Cacciola, Radiation Oncology Unit, Department of Biomedical, Dental Sciences and of Morphological and Functional Images, University of Messina, Messina 98124, Italy.
Email: alberto.cacciola0@gmail.com
Introduction

Patients with cancer may have up to 40% of possibility to develop spinal metastases during the course of their disease. However, in about 10% of the patients, they can represent the first clinical manifestation. Approximately 95% of patients demonstrate epidural metastases (vertebral body and the pedicle regions), the 5% will be present with intradural, and less than 1% with intramedullary metastases. Only 10% to 20% of the patients with spinal metastases will be alive for 2 years after the diagnosis.

Spinal metastasis is a complex condition that requires as therapeutic goals the palliation, the pain control, the spinal stability, the neurologic function maintenance, and the tumor control. The systemic treatments have improved providing extended life span in oncologic patients. The occurrence of spinal metastases in long-term survival patients encouraged the use of sophisticated treatment options, including stereotactic body radiation therapy (SBRT) and vertebroplasty. In this regard, the Spine Instability Neoplastic Score is one of the tools that provide a method for choosing between a surgical and alternative approach.

Pain is one of the most invalidating symptoms which occurs in more than 95% of patients with spinal metastases and it is present with specific characteristics: local, radicular, or mechanical pain. Aggressive surgical techniques (ie, spondylectomy) permit to obtain adequate pain control and stability. However, in patients with very limited life expectancy, vertebroplasty may be a valid alternative to control mechanical pain from vertebral body fractures in the absence of severe instability or spinal cord compression. Radiation therapy has recently developed new promising tools (ie, intensity-modulated radiation therapy, volumetric arc therapy, and SBRT) to treat spine metastases. In particular, SBRT permits to deliver a higher dose for fraction to the tumor, significantly reducing the dose to the spinal cord. The primary goal of spine SBRT is to maximize local tumor control of the involved spine while preserving neurologic function. To date, in patients with very short life expectancy, the single fraction (8-10 Gy) represent a valid alternative respect to 10 fractions of 3 Gy used in patients with better prognosis.

Hartsell et al reported no differences between the response of patients receiving 30 Gy in 10 treatment fractions and of those receiving 8 Gy in a single fraction, in terms of pain relief, narcotic relief, or pathologic fracture incidence. Overall, 89% of patients showed at least minimal relief of pain, with 53% obtaining complete relief and another 30% experiencing partial relief.

The use of advanced radiation techniques permits to deliver high dose with respect to the palliation. Stereotactic body radiation therapy allows the use of different contouring approaches (whole vs partial vertebral) for body contouring and has a beneficial effect on the local in-field recurrence. Stereotactic body radiation therapy is widely employed in clinical practice but only a few data exist about its use in simultaneous integrated boost (SIB) modality. In our department, we deliver SBRT with SIB (SBRT-SIB) using a CyberKnife (Accuray Inc, Sunnyvale, California) system which permits to plan a heterogeneous dose. The use of high-dose radiation on the spine with SBRT can induce vertebral compression fractures (VCFs), which are reported to develop more frequently (3% to 39%) than the more serious radiotherapy complication, that is, myelopathy (1% to 5%). Our hypothesis is that the use of hot spots on gross tumor volume (GTV) could decrease the risk of VCF and a dose of 8 Gy/1Fx could be valid to treat whole vertebral body.

Methods

Among all patients treated with SBRT for vertebral metastases in our center from December 2007 to July 2018, we have selected only patients treated with SBRT-SIB. Inclusion criteria were oligometastatic or oligorecurrent disease; life expectancy >6 months; no extradural spinal cord compression; <3 vertebral sites involved.

The primary end points were the pain control at the time of the last follow-up and the time to local progression (TTLP), which was defined as the imaging-based disease progression compared with the magnetic resonance imaging (MRI) or positron emission tomography-computed tomography (PET/CT) at the time of treatment. The secondary end points were the overall survival (OS) and toxicity according to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) version 4.0.

The study was approved by the local institutional review board: Comitato Etico Interaziendale della Provincia di Messina. Protocol Number: 61/19. Informed consent was obtained from the patients.

1. Imaging and treatment

Treatments were delivered using the CyberKnife, an image-guided, frameless, LINAC-based, 6 MV radiosurgery system.
with Xsight Spine Tracking System for image-guided radiation therapy. The patients were immobilized with a vacuum bag for imaging acquisition and treatment. The pretreatment imaging consisted of a thin-section multiplanar reconstruction-gradient echo volumetric study conducted on a Siemens Magnetom 1.5 T MRI imaging system (Siemens, Erlangen, Germany), performed with the following parameters: repetition time 9.7 milliseconds, echo time 4 milliseconds, matrix 200 × 256, flip angle 1, orientation sagittal. A multislice body CT was also performed using a multislice scanner, Siemens Sensation 16 (Siemens).

2. Target, organ at risk delineation and treatment planning

Manual contouring of the tumor and the critical volumes was performed on the coregistered MRI and CT data sets in the axial plane with simultaneous display of contours on reconstructed orthogonal images (Figure 1). The planning target volume (PTV) was delineated on the entire vertebrae of the involved levels with expansion of 1 mm in all direction and −1 mm in the cavitation around the spinal canal. The GTV was defined on the MR, CT, or PET-CT. The PTV-boost was outlined on a concept of anatomical target volume as a function of the topography of GTV and of the macroscopically involved elements of the vertebra (body, peduncles, transverse process, and spinous process; Figure 1). The PTV-boost plus PTV was used for SBRT-SIB prescription dose delivery. The spinal cord was contoured on the MRI. No spinal cord volume expansion was performed but the spinal canal was contoured on the CT images. Additional organs-at-risk were delineated in function of the anatomical districts (pharynx, esophagus, lungs, kidneys, bowel, etc).

The Multiplan Treatment Planning System (Accuray Inc) was used for inverse planning. An inhomogeneous prescription in 1 fraction has been applied to create the hot spot of dose for the PTV-boost (SBRT-SIB).21-23 The hot spot was obtained with a prescription dose of 8 to 10 Gy to isodose line of 50% in order to obtain a PTV coverage of at least 95%. By tuning goals and constraints of the inverse planning, we were able to shift the whole dose from 16 to 20 Gy on the PTV Boost.

3. Patients assessment

Follow-up imaging was based on our institutional practice, consisting of a full spine MRI study at 3-month intervals and PET/CT after 6 months. Time to local progression was defined as the time from treatment to a radiological documented disease progression in the treated spine using RECIST-Criteria (Revised Guidelines, Version 1.1, 2009).27 The OS was defined as the duration from irradiation to patient death. The acute and late toxicity evaluations were performed according to NCI CTCAE version 4.0, 3 and the pain was assessed using the numeric rating scale (NRS).

4. Statistical data analysis and parameters

Because of the relative rarity of spinal metastases requiring SBRT-SIB, we decided to accrue prospectively a consecutive series of patients during a period as long as 12 years to obtain a consistent population with precisely defined characteristics and homogeneously treated.
Estimates of TTLP and OS were calculated using the Kaplan-Meier method and the log-rank test was used to compare survival curves. Statistical tests were 2-tailed and a P value < .05 was considered statistically significant. All data were analyzed using the SPSS version 24.0 software package (IBM Corporation, Armonk, New York).

Results

A total of 20 patients with spine metastases and 22 metastatic sites were treated in our center with SBRT-SIB between December 2007 and July 2018. Clinical and main demographic characteristics of patients were summarized in Table 1. All patients were treated at the University Hospital of Messina, Italy. Details of treatment characteristics are shown in Table 2. The median follow-up was 35 months (range: 12-110).

Stereotactic body radiation therapy–simultaneous integrated boost treatments were delivered with doses of 8 to 10 Gy in 1 fraction to isodose line of 50% (\(D_{\text{max}} = 20\) Gy; Median SIB-Biologically Equivalent Dose [BED]10 = 41.6 Gy (41.6-60); Equivalent Dose in 2 Gy per fraction [EQD2] Max = 50.00 Gy).

1. Time to local progression.

The median TTLP for the overall sample was not reached and the actuarial 1-, 2-, and 3-years local progression rate was 86.36% (Figure 2). Only 2 patients (10%) had both imaging and clinical evidence of local progression 6 months after treatment and 1 patient (5%) 9 months after the treatment.

2. Overall survival

The median OS for the entire cohort was 38 months with actuarial survival rates at 1, 2, and 3 years of 100%, 89.95%, and 59.31%, respectively (Figure 3).

3. Toxicity and pain control

None of the patients experienced neither radiation adverse events (grade 1-4) nor reported pain flair reaction. None of the

| Table 1. Patients Characteristics. |
|-----------------------------------|
| **Variable** | **Value** |
| Patients | 20 |
| Treatments | 22 |
| Age (years) | Median 63 |
| | Range (38-86) |
| Sex | Male 11 |
| | Female 9 |
| Primitive tumor | Breast 7 |
| | Lung 3 |
| | Kidney 2 |
| | Prostate 3 |
| | Others 5 |
| Oligometastatic | Yes 12 |
| | No 8 |

| Table 2. Treatments Characteristics. |
|-------------------------------------|
| **Characteristics** | **Total** |
| Treatments | 22 |
| Location | 3 |
| | Thoracic 12 |
| | Lumbar 7 |
| Histological | Breast 9 |
| | Lung 3 |
| | Kidney 2 |
| | Prostate 3 |
| | Others 5 |
| Oligometastatic lesions | Yes 13 |
| | No 9 |

Abbreviation: SBRT-SIB, stereotactic body radiation therapy–simultaneous integrated boost.

![Figure 2. Time to local progression (TTLP) for the overall sample.](image2)

![Figure 3. Overall survival (OS) for the entire sample.](image3)
patients included in our series experienced VCF. In 17 of 20 patients, a complete pain remission (CR) was observed and 3 of 20 patients had a partial pain remission (PR; CR + PR: 100%).

**Discussion**

Stereotactic body radiation therapy is often used in the treatment of vertebral metastases for the characteristic sharp dose decline outside the target volume. In spine-SBRT, the definition of the clinical volume tumor including the GTV often involves the entire vertebral volume. The goal is the maximum tumor control while preserving neurological functions. This concept has led to research for an SIB that shapes the dose to the local control of the tumor with significant dose reductions at the spinal cord (Table 3).20,28,29 Several studies suggested that SBRT provides 70% to 100% rate of 1-year local control across clinical scenarios.17,30-32 When performed as the primary treatment modality, SBRT is associated with long-term local control rate of 80% to 95% for patients with spinal metastases.17,33-35 Analogously, in the adjuvant setting following surgery, SBRT provides local control rates ranging from 70% to 100%.32,36 We observed that SBRT-SIB provides 1-, 2-, and 3-year TTLP actuarial rates of 86.36%, in line with previous SBRT reports. Figure 4 reports an SBRT-SIB treatment plan and the radiological results 6 months after the treatment.

With a radiation dose of 16 to 20 Gy in a single fraction, the tumor volume decreases of the 70% with a tumor regression of the 65% at 2 months. On the other hand, it has been reported that high-dose SBRT may increase the risk of VCF (3% to 39%) and myelopathy (1% to 5%).7-11,20 Our hypothesis holds that a SIB to the bone metastasis might overcome this problem. Despite our findings should be interpreted with caution, no VCF and myelopathy were reported in our series.

In this regard, Mantel et al have recently identified frequency, clinical relevance, and risk factors for VCF after spine SBRT with long-term follow-up in 56 patients (61 lesions) within a prospective multicenter phase 2 study (NCT01594892).37 Post-SBRT VCF developed in 21 lesions (34.4%): of these, 10 lesions (16.4%) showed a progressive VCF, while a new VCF occurred in 11 lesions (18.0%). If on the one hand, SBRT dose did not significantly correlate to VCF in the univariate analysis, receiver operating characteristics analysis revealed that a relative involvement of 34.5% of the vertebral body best predicted a post-SBRT VCF with an area under the curve of 0.864, a sensitivity of 77.8%, and a specificity of 89.7%. In addition, in the same study,37 a BED10 greater than 59.5 Gy has been delivered to the high dose PTV; in our patients, a median BED10 dose of 41.6 Gy has been reached. This could further justify the absence of VCF in our series.

In addition to long-term local control, one of the main purposes of spine SBRT is the pain control. Available data suggest that the 1-year actuarial pain control rate is 84% with doses higher than 14 Gy delivered in a single fraction.30,38 The use of various SBRT doses in the range of 16 to 24 Gy has obtained higher pain control compared with 14 Gy in a single fraction (90%).14,39,40 It is worth to note that we obtained an overall pain control in 100% cases, however, due to the small sample size, this data should be regarded with caution and the results may also depend on the use of a high dose of dexamethasone. Finally,
in our study, we report a marginal failure rate of 5% after spinal SBRT-SIB, which is in line with previous studies.\textsuperscript{15,41}

Conclusions

This study suggests that SBRT-SIB provides an excellent TTLP in patients with vertebral metastases as well as a low in-field recurrent disease rate. In the present series, no VCF and myelopathy were reported. However, considering the relatively small sample size, further studies should be promoted to demonstrate the advantage of 8 to 10 Gy to isodose line of 50% in a single fraction in SBRT-SIB modality in patients with vertebral lesions.

Authors' Note

The study was approved by the local institutional review board: Comitato Etico Interaziendale della Provincia di Messina. Protocol Number: 61/19. Isidora Ielo is also affiliated with Medical Physics Unit, A.O.U. “G. Martino”, Messina, Italy.

Acknowledgments

Authors would like to thank ab medica S.p.A for supporting the Arti.

declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by ab medica S.p.A.

ORCID iD

Alberto Cacciola \( \text{https://orcid.org/0000-0001-9412-4116} \)

References

1. Walsh GL, Gokaslan ZL, McCutcheon IE, et al. Anterior approaches to the thoracic spine in patients with cancer: indications and results. \textit{Ann Thorac Surg}. 1997;64(6):1611-1618. doi:10.1016/s0003-4975(97)01034-5.
2. Ortiz Gómez JA. The incidence of vertebral body metastases. \textit{Int Orthop}. 1995;19(5):309-311. doi:10.1007/bf00181116.
3. Perrin RG, Livingston KE, Arabii B. Intradural extramedullary spinal metastasis. \textit{J Neurosurg}. 1982;56(6):835-837. doi:10.3171/jns.1982.56.6.0835.
4. Schick U, Marquardt G, Lorenz R. Intradural and extradural spinal metastases. \textit{Neurosurg Rev}. 2001;24(1):1-5. doi:10.1007/pl00011959.
5. Laufer I, Rubin DG, Lis E, et al. The NOMS framework: approach to the treatment of spinal metastatic tumors. \textit{Oncologist}. 2013;18(6):744-751. doi:10.1634/theoncologist.2012-0293.
6. Bilsky MH, Laufer I, Burch S. Shifting paradigms in the treatment of metastatic spine disease. \textit{Spine (Phila Pa 1976)}. 2009;34(suppl):S101-S107. doi:10.1097/BRs.0b013e3181b4a5b2.
7. Fisher CG, DiPaola CP, Ryken TC, et al. A novel classification system for spinal instability in neoplastic disease: an evidence-based approach and expert consensus from the Spine Oncology Study Group. \textit{Spine (Phila Pa 1976)}. 2010;35(22):E1221-E1229. doi:10.1097/brs.0b013e3181e16ea2.
8. Fourney DR, Frangou EM, Ryken TC, et al. Spinal Instability Neoplastic Score: an analysis of reliability and validity from the Spine Oncology Study Group. \textit{J Clin Oncol}. 2011;29(22):3072-3077. doi:10.1200/jco.2010.34.3897.
9. Gokaslan ZL. Spine surgery for cancer. \textit{Curr Opin Oncol}. 1996;8(3):178-181. http://www.ncbi.nlm.nih.gov/pubmed/8804815. Accessed August 13, 2019.
10. Fourney DR, Gokaslan ZL. Use of “MAPS” for determining the optimal surgical approach to metastatic disease of the thoracolumbar spine: anterior, posterior, or combined. \textit{J Neurosurg Spine}. 2005;2(1):40-49. doi:10.3171/spi.2005.2.1.0040.
11. Fourney DR, Abi-Said D, Lang FF, McCutcheon IE, Gokaslan ZL. Use of pedicle screw fixation in the management of malignant spinal disease: experience in 100 consecutive procedures. \textit{J Neurosurg}. 2001;94(1 suppl):25-37. http://www.ncbi.nlm.nih.gov/pubmed/11147865. Accessed August 28, 2019.
12. Fourney DR, Schomer DF, Nader R, et al. Percutaneous vertebroplasty and kyphoplasty for painful vertebral body fractures in cancer patients. \textit{J Neurosurg}. 2003;98(1 suppl):21-30. http://www.ncbi.nlm.nih.gov/pubmed/12546384. Accessed August 28, 2019.
13. Ryu S, Fang Yin F, Rock J, et al. Image-guided and intensity-modulated radiosurgery for patients with spinal metastasis. \textit{Cancer}. 2003;97(8):2013-2018. doi:10.1002/cncr.11296.
14. Gerszten PC, Burton SA, Welch WC, et al. Single-fraction radiosurgery for patients with spinal metastasis. \textit{Cancer}. 2005;118:5069-5077. doi:10.1002/cncr.21467.
15. Chang EL, Shiu AS, Mendel E, et al. Phase I/II study of stereotactic body radiotherapy for spinal metastasis and its pattern of failure. \textit{J Neurosurg Spine}. 2007;7(2):151-160. doi:10.3171/SPI/07/08/151.
16. Degen JW, Gagnon GJ, Voyadzis JM, et al. CyberKnife stereotactic radiosurgical treatment of spinal tumors for pain control and quality of life. \textit{J Neurosurg Spine}. 2005;2(5):540-549. doi:10.3171/spi.2005.2.5.0540.
17. Yamada Y, Bilsky MH, Lovelock DM, et al. High-dose, single-fraction image-guided intensity-modulated radiotherapy for metastatic spinal lesions. \textit{Int J Radiat Oncol Biol Phys}. 2008;71(2):484-490. doi:10.1016/j.ijrobp.2007.11.046.
18. Hartsell WF, Scott CB, Bruner DW, et al. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. \textit{J Natl Cancer Inst}. 2005;97(11):798-804. doi:10.1093/jnci/dji139.
19. Bilsky MH, Laufer I, Fourney DR, et al. Reliability analysis of the epidural spinal cord compression scale. \textit{J Neurosurg Spine}. 2010;13(3):324-328. doi:10.3171/2010.3.SPINE09459.
20. Lubgan D, Ziegler A, Semrau S, Lambrecht U, Lettmaier S, Fietkau R. Effective local control of vertebral metastases by simultaneous integrated boost radiotherapy: preliminary results. \textit{Strahlentherapie und Onkol}. 2015;191:264-271. doi:10.1007/s00066-014-0780-4.
21. Pontoriero A, Iatti G, Pergolizzi S. A case report of a patient with squamous cell carcinoma of the face irradiated using a stereotactic
technique. *Radiat Oncol J*. 2015;33(3):261-264. doi:10.3857/roj.2015.33.3.261.

22. Pontoriero A, Iati G, Aiello D, Pergolizzi S. Stereotactic radiotherapy in the retreatment of recurrent cervical cancers, assessment of toxicity, and treatment response: initial results and literature review. *Technol Cancer Res Treat*. 2016;15(6):759-765. doi:10.1177/1533043415608740.

23. Pontoriero A, Iati G, Mondello S, et al. High-dose robotic stereotactic body radiotherapy in the treatment of patients with prostate cancer: preliminary results in 26 patients. *Technol Cancer Res Treat*. 2016;15(1):179-185. doi:10.1177/1533043414566994.

24. Cacciola A, Pontoriero A, Iati G, et al. Letter to the editor. The unmet needs for prognostication of long-term outcomes in multiple sclerosis-related trigeminal neuralgia radiosurgery. *J Neurosurg*. 2019;1-2. doi:10.3171/2019.2.JNS19426.

25. Sahgal A, Whyne CM, Ma L, Larson DA, Fehlings MG. Vertebral compression fracture after stereotactic body radiotherapy for spinal metastases. *Lancet Oncol*. 2013;14(8):e310-e320. doi:10.1016/S1470-2045(13)70101-3.

26. Ozdemir Y, Torun N, Guler OC, et al. Local control and vertebral compression fractures following stereotactic body radiotherapy for spine metastases. *JBone Oncol*. 2019;15:100218. doi:10.1016/j.jbo.2019.100218.

27. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer*. 2009;45(2):228-247. doi:10.1016/j.ejca.2008.10.026.

28. Murai T, Murata R, Manabe Y, et al. Intensity modulated stereotactic body radiation therapy for single or multiple vertebral metastases with spinal cord compression. *Pract Radiat Oncol*. 2014;4(6):e231-e237. doi:10.1016/j.prro.2014.02.005.

29. Yang H, Cai BN, Wang XS, et al. Dose evaluation of fractionated schema and distance from tumor to spinal cord for spinal SBRT with simultaneous integrated boost: a preliminary study. *Med Sci Monit*. 2016;22:598-607. doi:10.12659/MSM.897146.

30. Gerszten PC, Burton SA, Ozhassooglu C, Welch WC. Radiosurgery for spinal metastases: clinical experience in 500 cases from a single institution. *Spine (Phila Pa 1976)*. 2007;32:193-199. doi:10.1097/01.brs.0000251863.76595.a2.

31. Al-Omair A, Masucci L, Masson-Cote L, et al. Surgical resection of epidural disease improves local control following postoperative spine stereotactic body radiotherapy. *Neuro Oncol*. 2013;15:1413-1419. doi:10.1093/neuonc/not101.

32. Laufer I, Iorgulescu JB, Chapman T, et al. Local disease control for spinal metastases following “separation surgery” and adjuvant hypofractionated or high-dose single-fraction stereotactic radiotherapy: outcome analysis in 186 patients. *J Neurosurg Spine*. 2013;18:207-214. doi:10.3171/2012.11.SPINE12111.

33. Sellin JN, Reichardt W, Bishop AJ, et al. Factors affecting survival in 37 consecutive patients undergoing de novo stereotactic radiosurgery for contiguous sites of vertebral body metastasis from renal cell carcinoma. *J Neurosurg Spine*. 2015;22:52-59. doi:10.3171/2014.9.SPINE1482.

34. Anand AK, Venkadamanickam G, Punnakal AU, et al. Hypofractionated stereotactic body radiotherapy in spinal metastasis—with or without epidural extension. *Clin Oncol*. 2015;27(6):345-352. doi:10.1016/j.clon.2015.01.035.

35. Guckenberger M, Mantel F, Gerszten PC, et al. Safety and efficacy of stereotactic body radiotherapy as primary treatment for vertebral metastases: a multi-institutional analysis. *Radiat Oncol*. 2014;9(1):226. doi:10.1186/s13046-014-0226-2.

36. Bate BG, Khan NR, Kimball BY, Gabrick K, Weaver J. Stereotactic radiosurgery for spinal metastases with or without separation surgery. *J Neurosurg Spine*. 2015;22(4):409-415. doi:10.3171/2014.10.SPINE14252.

37. Mantel F, Sweeney RA, Klement RJ, et al. Risk factors for vertebral compression fracture after spine stereotactic body radiation therapy: long-term results of a prospective phase 2 study. *Radiother Oncol*. 2019;141:62-66. doi:10.1016/j.radonc.2019.08.026.

38. Ryu S, Jin R, Jin JY, et al. Pain control by image-guided radiosurgery for solitary spinal metastasis. *J Pain Symptom Manage*. 2008;35:292-298. doi:10.1016/j.jpainsymman.2007.04.020.

39. Gerszten PC, Burton SA, Ozhasoglu C, et al. Stereotactic radiosurgery for spinal metastases from renal cell carcinoma. *J Neurosurg Spine*. 2005;3(4):288-295. doi:10.3171/spi.2005.3.4.0288.

40. Garg AK, Shiu AS, Yang J, et al. Phase 1/2 trial of single-session stereotactic body radiotherapy for previously unirradiated spinal metastases. *Cancer*. 2012;118(20):5069-5077. doi:10.1002/cncr.27530.

41. Ryu S, Rock J, Rosenblum M, Jae HK. Patterns of failure after single-dose radiosurgery for spinal metastasis. *J Neurosurg*. 2004;101(suppl 3):402-405.